This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife
by Zacks Equity Research
The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.
Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business
by Zacks Equity Research
Express Scripts (ESRX) is consistently trying to expand its core PBM business.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
5 MedTech Stocks for Stellar Returns in Q3
by Zacks Equity Research
Here we take a sneak peek into two burning issues that are likely to impact the quarterly numbers in the MedTech fraternity.
4 Top Growth Picks as MedTech Battle Rages On
by Zacks Equity Research
Trump's Obamacare replacement saga has made growth picks great opportunities for investors in MedTech sector.
Pacific Biosciences, Bluebee Team Up for De Novo Sequencing
by Zacks Equity Research
With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.
QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite
by Zacks Equity Research
QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.
Illumina (ILMN) Strong on Product Launches, Competition Rife
by Zacks Equity Research
Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.
Fresenius Medical (FMS) Well Poised on Growth Strategy 2020
by Zacks Equity Research
Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.
Boston Scientific Grows on New Products, Currency Woe Ails
by Zacks Equity Research
Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.
DaVita Banks on Acquisitions, Escalating Expenses a Concern
by Zacks Equity Research
DaVita HealthCare Partners' (DVA) focus on acquisitions will boost the company's expansion. However, rising expenses remains headwind.
Hurricane Maria to Hurt Medtronic in Q2, FY18 View Intact
by Zacks Equity Research
Medtronic (MDT) expects normal manufacturing process in Puerto Rico to resume in full force in the coming weeks with considerable repairing done in the aftermath of Hurricane Maria.
Teleflex (TFX) Hits a 52-Week High on NeoTract Acquisition
by Zacks Equity Research
NeoTract acquisition is expected to generate mid-single digit constant currency revenue growth for the next several years and enhance Teleflex's (TFX) margins.
Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm
by Zacks Equity Research
Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.
Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.
QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.
Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval
by Zacks Equity Research
Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.
PerkinElmer Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
PerkinElmer's (PKI) portfolio has not only boosted the company's organic growth trajectory but has also helped boost market share worldwide. Solid estimate revision trend boosts investor confidence.
Masimo (MASI) Launches Trace Data and Reporting Tool in US
by Zacks Equity Research
Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.
Genomic Health's Cost Pressure Mounts, Cancer Tests Strong
by Zacks Equity Research
Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.
Integra Rides High on Product Launches, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.
Henry Schein to Offer CAS' Fully-Automated Cognivue Device
by Zacks Equity Research
Henry Schein (HSIC) is consistently working toward boosting its Medical segment.
Hill-Rom (HRC) Rides on Product Launches, Competition Rife
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation through research and development. Its product launches slated for the fourth quarter are boosting investors' confidence.
Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line
by Zacks Equity Research
Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen'S (ABC) growth story is expected to be stunted by tepid performance at PharMEDium. Also steep competition is a cause of concern.